181 filings
Page 7 of 10
6-K
VALN
Valneva SE
16 Dec 21
Valneva Announces Positive Homologous Booster Data for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
5:00pm
6-K
VALN
Valneva SE
9 Dec 21
Valneva Signs Advance Purchase Agreement with Bahrain for Inactivated COVID-19 Vaccine VLA2001
12:00pm
6-K
VALN
Valneva SE
3 Dec 21
Valneva and IDT Biologika Announce Collaboration for Production of Inactivated COVID-19 Vaccine VLA2001
5:00pm
6-K
VALN
Valneva SE
26 Nov 21
Valneva Signs Purchase Agreement with European Commission for its Inactivated COVID-19 Vaccine VLA2001
12:00pm
6-K
VALN
Valneva SE
18 Nov 21
Valneva to Present its Chikungunya Vaccine Candidate at the ASTMH 2021 Annual Meeting
1:00pm
6-K
VALN
Valneva SE
10 Nov 21
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
11:00am
6-K
VALN
Valneva SE
3 Nov 21
Valneva Announces Closing of Approximately $102.0 Million Global Offering
5:00pm
6-K
VALN
Valneva SE
1 Nov 21
Current report (foreign)
5:00pm
424B4
VALN
Valneva SE
1 Nov 21
Prospectus supplement with pricing info
4:06pm
6-K
VALN
Valneva SE
29 Oct 21
Valneva Announces the Pricing of its Global Offering of American Depositary Shares and Ordinary Shares
4:30pm
EFFECT
VALN
Valneva SE
29 Oct 21
Notice of effectiveness
12:15am
6-K
VALN
Valneva SE
27 Oct 21
Valneva Announces Launch of Proposed Global Offering of American Depository Shares and Ordinary Shares
5:00pm
F-1
VALN
Valneva SE
26 Oct 21
Registration statement (foreign)
5:04pm
CORRESP
VALN
Valneva SE
26 Oct 21
Correspondence with SEC
12:00am
CORRESP
VALN
Valneva SE
26 Oct 21
Correspondence with SEC
12:00am
UPLOAD
VALN
Valneva SE
25 Oct 21
Letter from SEC
12:00am
DRS
VALN
Valneva SE
20 Oct 21
Draft registration statement
12:00am
6-K
VALN
Valneva SE
18 Oct 21
Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
8:00am
6-K
VALN
Valneva SE
5 Oct 21
Valneva to Present and Hold Investor Meetings at the Guggenheim Vaccines and Infectious Disease Conference
9:30am
6-K
VALN
Valneva SE
29 Sep 21
Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate
9:30am